0.95 USD
+0.03 (+3.26%)
0.9282 USD
-0.02 (-2.29%)
CRIS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. CRIS has a bad profitability rating. Also its financial health evaluation is rather negative. CRIS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year CRIS has reported negative net income.
- CRIS had a negative operating cash flow in the past year.
- In the past 5 years CRIS always reported negative net income.
- In the past 5 years CRIS always reported negative operating cash flow.
1.2 Ratios
- CRIS's Return On Assets of -132.25% is on the low side compared to the rest of the industry. CRIS is outperformed by 81.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -132.25% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-72.86%
ROA(5y)-52.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 99.47%, CRIS belongs to the top of the industry, outperforming 98.67% of the companies in the same industry.
- CRIS's Gross Margin has been stable in the last couple of years.
- CRIS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.47% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y0.85%
2. Health
2.1 Basic Checks
- CRIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, CRIS has more shares outstanding
- Compared to 5 years ago, CRIS has more shares outstanding
- There is no outstanding debt for CRIS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- CRIS has an Altman-Z score of -67.92. This is a bad value and indicates that CRIS is not financially healthy and even has some risk of bankruptcy.
- CRIS has a Altman-Z score of -67.92. This is amonst the worse of the industry: CRIS underperforms 92.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -67.92 |
ROIC/WACCN/A
WACC8.86%
2.3 Liquidity
- CRIS has a Current Ratio of 0.70. This is a bad value and indicates that CRIS is not financially healthy enough and could expect problems in meeting its short term obligations.
- CRIS has a Current ratio of 0.70. This is amonst the worse of the industry: CRIS underperforms 88.57% of its industry peers.
- A Quick Ratio of 0.70 indicates that CRIS may have some problems paying its short term obligations.
- The Quick ratio of CRIS (0.70) is worse than 88.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.7 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 53.01% over the past year.
- Looking at the last year, CRIS shows a quite strong growth in Revenue. The Revenue has grown by 13.56% in the last year.
- Measured over the past years, CRIS shows a small growth in Revenue. The Revenue has been growing by 1.75% on average per year.
EPS 1Y (TTM)53.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.18%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y0.8%
Revenue growth 5Y1.75%
Sales Q2Q%8.36%
3.2 Future
- CRIS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.21% yearly.
- Based on estimates for the next years, CRIS will show a very strong growth in Revenue. The Revenue will grow by 57.54% on average per year.
EPS Next Y63.06%
EPS Next 2Y31.9%
EPS Next 3Y22.56%
EPS Next 5Y14.21%
Revenue Next Year17.66%
Revenue Next 2Y12.66%
Revenue Next 3Y28.44%
Revenue Next 5Y57.54%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for CRIS. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRIS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as CRIS's earnings are expected to grow with 22.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.9%
EPS Next 3Y22.56%
5. Dividend
5.1 Amount
- CRIS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CURIS INC / CRIS FAQ
What is the fundamental rating for CRIS stock?
ChartMill assigns a fundamental rating of 2 / 10 to CRIS.
What is the valuation status of CURIS INC (CRIS) stock?
ChartMill assigns a valuation rating of 1 / 10 to CURIS INC (CRIS). This can be considered as Overvalued.
How profitable is CURIS INC (CRIS) stock?
CURIS INC (CRIS) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for CRIS stock?
The Earnings per Share (EPS) of CURIS INC (CRIS) is expected to grow by 63.06% in the next year.